Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05615233
Other study ID # STUDY00004376
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 5, 2024
Est. completion date August 31, 2024

Study information

Verified date June 2024
Source University of Texas at Austin
Contact Eun-Ok Im, PhD, MPH
Phone 512 471-4100
Email eunok.im@austin.utexas.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the proposed study is to preliminarily evaluate Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of patients living with Alzheimer's disease (TACAD) in improving health outcomes of Asian American midlife women who are family caregivers of persons living with Alzheimer's disease (AACA) and their care recipients.


Description:

The purpose of the proposed study is to preliminarily evaluate a technology-based program in improving health outcomes of Asian American midlife women who are family caregivers of persons living with Alzheimer's disease (AACA) and their care recipients. The participants of this randomized clinical trial will be 60 self-reported AACA aged 40 to 65 years old who identify as Chinese or Korean; are family caregivers of PLAD; can read and write English, Mandarin Chinese or Korean; who reside in the U.S.; and have access to the Internet through computers or mobile devices. Participants will be recruited through both online and offline communities/groups for Asian Americans. The recruitment settings are identified through both Internet searches and recommendations by research team members. When potential participants of Phase 2 visit the project Web site (after receiving/reviewing a study announcement), they will be asked to review the informed consent. When participants click I agree to participate, they will have given their consent. No identity information, including IP addresses, will be attached to any of the individual or group data. Therefore, research participants will not be identifiable directly or through the identifying information linked to subjects. Only research staff will have access to the data. Phase 2 study consists of two groups of research participants: (a) a control group who does not use the technology-based program, but uses the information on Alzheimer's Disease and caregiving by the Alzheimer's Association website; (b) an intervention group who uses the technology-based program and the information by the Alzheimer's Association website. Both groups will participate in the study for 3 months. During the research process, both groups are asked to fill out the Internet survey questionnaire (through the REDCap system) at three times (pre-test, post-1 moth, and post 3-months); if requested, paper-and-pencil questionnaires will be provided/used, or research staff will assist in administering the Internet surveys over the phone. Data will be collected only through the Internet survey, and each survey takes about 20 to 30 minutes to complete. Only for the intervention group, weekly group and individual coaching/support (max 1hr/week) by culturally matched bilingual interventionists will be provided through the online forum and chatting functions on the project website, phone calls, or text messages through ethnic-specific communication apps, and the participants are asked to use the educational modules, virtual reality app, and online resources that are available on the project website. The data collected through the Internet surveys will be stored on the HIPAA compliant clouds maintained by Emory University. All documentation related to the study will be also stored on the HIPAA compliant clouds maintained by Emory University.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date August 31, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: - self reported AACA. - Participants will be included if, by self-report, they are Asian American women aged 40 to 65 years old who identify as Chinese or Korean; - are family caregivers of PLAD; - can read and write English, Mandarin Chinese or Korean; - who reside in the U.S.; - have access to the Internet through computers or mobile devices. - Participants must be providing at least 4 hours per day unpaid assistance, on average, for a community-dwelling person in the early-middle stage of illness (Clinical Dementia Rating of 1) for whom there is no plan for institutionalization in six months. - Caregivers may or may not reside with their care recipient. Exclusion Criteria: - Those who used the AA website previously and/or participated in other studies related to AD will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
TACAD
Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of PLAD (TACAD). It includes four components in three languages (English, MandarinChinese, and Korean): 2 sub-ethnic specific social media sites; interactive online educational modules; online resources; and a VR component based on "A Walk Through Dementia (WTD)"
Alzheimer's Association website
The webpage on caregiving includes information on caregiving, care option, financial/legal planning, caregiver health, daily care, stages and behaviors, and safety. The content will be available in the three languages at the project website.

Locations

Country Name City State
United States The University of Texas at Austin Austin Texas
United States University of Texas at Austin Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas at Austin

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Multidimensional Caregiver Strain Index from baseline Is a questionnaire that evaluates caregiver's health outcome. Total possible score range is 0-26. Higher score correlates with worse outcome. Baseline, 1 months post intervention, 3 months post intervention
Primary Change in Perceived Stress Scale score from baseline Measure of individual stress. Possible score range is 0-40 with higher scores indicating higher perceived stress. Baseline, 1 months post intervention, 3 months post intervention
Primary Change in Acculturation Stress Scale (ASS) score from baseline Score range is 0-36. Higher score correlates with worse outcome (higher stress) Baseline, 1 months post intervention, 3 months post intervention
Primary Change in Social Readjustment Rating Scale (SRRS) score from baseline This questionnaire asks about number the of events in the last 12 months. Total score range 0-41 and higher score correlates with higher stress. Baseline, 1 months post intervention, 3 months post intervention
Primary Change in Midlife Women's Symptom Index from baseline This questionnaire measures physical and psychological symptoms during the last 6 months. It includes 73 questions that can be rated from 0-4. Possible score ranges from 0-292. Higher score correlates with worse outcome. Baseline, 1 months post intervention, 3 months post intervention
Primary Change in EQ-5D-5L scale score from baseline This is a generic health status measure by the EuroQol Group to measure quality of daily life. It includes five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/ depression) with five responses for each dimension (no problem to extreme problems); each digit in the five-digit codes refers to the status of each dimension, ranging from 1 (no problem) to 5 (severe problem). Possible score ranges from 0 to 100. A higher score in the EQ-5D-5L indicated better health-related Quality of Life. Baseline, 1 months post intervention, 3 months post intervention
Primary Change in Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score from baseline This questionnaire measures the cognitive status of care recipients. Total possible score ranges from 8-40. Higher score correlates with worse outcome. Baseline, 1 months post intervention, 3 months post intervention
Primary Change in Lawton ADL/IADL Scale score from baseline This questionnaires measures instrumental activities of daily living. The Lawton IADL scale contains eight items, with a summary score from 0 (low function) to 8 (high function). Possible total score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men. The higher the score, the greater the person's abilities. Baseline, 1 months post intervention, 3 months post intervention
Primary Change in Revised Memory and Behavior Problem Checklist score from baseline This outcome measures behavioral and psychological symptoms of care recipients. Total possible score ranges between 0-96 with higher score correlating with worse outcome. Baseline, 1 months post intervention, 3 months post intervention
Primary Change in Neuropsychological Inventory Questionnaire score from baseline This questionnaire measures care recipients' mood status. This is a 12-item inventory assessing severity of mood states or behaviors reflecting mood. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress). Total possible score ranges 0 to 144. Baseline, 1 months post intervention, 3 months post intervention
Primary Change in Quality of Life Scale in Alzheimer's Disease score from baseline This questionnaire assesses quality of life (QOL) in 13 domains on a one 4-point Likert scale. It is used as a self-report and surrogate-report instrument. It uses a scale of 1-4 (poor, fair, good, or excellent) to rate a variety of life domains, including the patient's physical health, mood, relationships, activities, and ability to complete tasks. Total possible score ranges 13 to 52. Baseline, 1 months post intervention, 3 months post intervention
Secondary Change in Caregiver Activity Survey score from baseline This survey measures the time caregivers spend aiding Alzheimer's patients with their day-to-day activities. The instrument includes 6 areas of caregiving activities (communicating with the person, using transportation, dressing, eating, looking after one's appearance, and supervising the person). Each items score reflects how many minutes is spent in that activity during the day prior to each assessment, and total scores are calculated in hours. Total possible score ranges from 0 to 24 hours. Higher scores indicate greater caregiver distress. Baseline, 1 months post intervention, 3 months post intervention
Secondary Change in Ways of Coping Scale score from baseline This scale measures caregivers' coping status. It is a 42-item scale with 4-point Likert responses that identifies emotion- and problem-focused coping responses of caregivers. Possible score range is 0-198. Higher score correlates with better outcome. Baseline, 1 months post intervention, 3 months post intervention
Secondary Change in Pearlin Mastery, Loss, and Competence Scale score from baseline This scale measures the extent to which an individual regards their life chances as being under their personal control rather than fatalistically ruled. Individual items use a 4-point Likert scale (1,"Strongly disagree" and 4,"Strongly agree"). Possible total score ranges 7 to 28. Higher scores indicate greater levels of mastery. Baseline, 1 months post intervention, 3 months post intervention
Secondary Change in Caregiver Assessment of Behavioral Skill Scale score from baseline This scale measures caregiving skills. This is a 17-item self-report assessment of behavioral management skills. Each item is measured on a 3-point Likert scale (0 = "seldom true" to 2 = "true most of the time"). Possible total score ranges from 0-34. Higher scores indicates greater behavioral skill. Baseline, 1 months post intervention, 3 months post intervention
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A